DGX vs LH
Quest Diagnostics and Labcorp, both Healthcare
Quest Diagnostics is the larger company at $22B against $21B. On trailing earnings DGX is the cheaper of the two at a P/E of 24.5 against 25.8, a gap that is only a bargain if the two are growing at similar rates. Over the past year DGX returned +28% against +14% for LH. The RyuScore puts DGX ahead, 63 against 60 out of 100.
| Figure | DGX | LH |
|---|---|---|
| Last close | $231 | $312 |
| Market cap | $22B | $21B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 24.5 | 25.8 |
| Dividend yield | n/a | 0.9% |
| 1-year return | +28% | +14% |
| 5-year return | +65% | +29% |
| RyuScoresector-relative, 1–10 | 63/100 | 60/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Quest Diagnostics
Revenue of $3.0B in Q2 2026, net income $320M. Its largest reported line is Diagnostic Information Services Business, 98% of the disclosed total.
Labcorp
Revenue of $3.7B in Q2 2026, net income $299M. Its largest reported line is Diagnostics, 78% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.